Testing the Impact of Pre-visit Priming for Medications

StatusEnrolling by Invitation
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Sep 15, 2026 → Dec 15, 2026
See other at-risk trials from Brigham and Women's Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Lead sponsor: Brigham and Women's Hospital to Brigham and Women's Hospital Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Primary completion pushed from Sep 15, 2026 to Dec 15, 2026
    • Study completion pushed from Nov 14, 2026 to Feb 15, 2027
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Notable Trial status changed: Not Yet Recruiting → Enrolling by Invitation
    • Study sites: 0 to 1
    • Start date changed from estimate of May 15, 2026 to Jun 10, 2026
    • Eligibility criteria expanded, about 12 words
    v4
  3. Notable Start date: Mar 2, 2026 to May 15, 2026
    • Primary completion pushed from Jul 2026 to Sep 15, 2026
    • Study completion pushed from Sep 2026 to Nov 14, 2026
    v3
  4. Notable Primary endpoint revised
    • Start date: Feb 2026 to Mar 2, 2026
    • Secondary endpoint revised
    v2
  5. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
We will use EHR data to identify eligible patients at BWH primary care clinics. Patients will be eligible if they have an upcoming primary care provider (PCP) appointment at an included BWH clinic, are ≥65 years, and are eligible for a medication target; exclusion criteria will include relevant EHR-documented allergies. After sharing patients with PCPs for potential opt-out, patients will be randomized 1:1 in REDCap® to intervention or usual care (no prompt). The intervention will include a pre-visit patient-facing prompt with information about the evidence-based medication target. If patients are eligible for multiple targets, one will be randomly selected. The primary clinical outcome will be measured on the day of the PCP visit using EHR data, depending on target: a) discontinuation or tapering order, or b) prescribing. Secondary outcomes will include a) these same measures in a 60-day follow-up period after the visit to capture any follow-up actions. We will use an intention-to-treat approach including patients regardless of whether the visit occurred. We plan to conduct the trial until 1700 patients are reached. We will also conduct exploratory mediation analyses of mechanisms through brief patient surveys with behavioral scales and PCP survey.
Trial Details
NCT Number NCT07281131
Lead Sponsor Brigham and Women's Hospital
Collaborators: National Institute on Aging (NIA), University of Southern California
Conditions
(from sponsor)
Deprescribing, Statin Prescribing
Enrollment 1,700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov